ABBV

AbbVie Inc
$285.84+$2.30+0.81%Price as of Nov 20, 2026, 3:56 PM ET

Key stats

Market cap
505B
Open
—
Day range
—
52-week range
$190.75 – $302.93
Volume
5.26M
Avg volume
5.17M

Earnings

Q3 FY26Miss
Expected$3.82
Actual$3.82
Q2 FY26
Actual$2.03
Q1 FY26
Actual$0.39
Q4 FY25
Actual$1.02

Next earnings call Feb 3, 2027

About

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.

Employees
57,000
Headquarters
North Chicago, IL